title: Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.
abstract: OBJECTIVE
  To compare the efficacy of taxane-based regimens in the first line setting retrospectively in Chinese patients with recurrent and/or metastatic esophageal cancer.
  
  
  METHODS
  We analyzed 102 recurrent and/or metastatic esophageal cancer patients who received taxanes-based regimens in a first-line setting from January 2009 to December 2013. Sixteen (15.7%) patients were administered Nab-PTX based chemotherapy and 86 patients (84.3%) received paclitaxel (PTX) or docetaxel (DTX) based chemotherapy. Patients in the PTX/DTX group could be further divided into TP (71 patients) and TPF (15 patients) groups.
  
  
  RESULTS
  The objective response rate (ORR) of all patients was 20.6%, and the disease control rate (DCR) was 67.6%. The median overall survival (OS) was 10.5 months (95% CI 10.1-16.4) and the median progression-free survival (PFS) was 6.04 months (95% CI 5.09-7.91). The DCR was higher in the TPF group than the TP group (93.3% vs. 59.1%; p = 0.015 ). There were no significant differences in ORR, OS, and PFS among Nab-PTX, TPF and TP groups.
  
  
  CONCLUSIONS
  The three regimens of Nab-PTX based, TP and TPF proved active in a first line setting of Chinese patients with recurrent and/or metastatic esophageal cancer, and should thus be regarded as alternative treatments.
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China E-mail : xialiangping@163.com.
authors.forename: Chang
authors.initials: C
authors.lastname: Jiang
authors.forename: Fang-Xin
authors.initials: FX
authors.lastname: Liao
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Rong
authors.forename: Qiong
authors.initials: Q
authors.lastname: Yang
authors.forename: Chen-Xi
authors.initials: CX
authors.lastname: Yin
authors.forename: Wen-Zhuo
authors.initials: WZ
authors.lastname: He
authors.forename: Xiu-Yu
authors.initials: XY
authors.lastname: Cai
authors.forename: Gui-Fang
authors.initials: GF
authors.lastname: Guo
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Qiu
authors.forename: Xu-Xian
authors.initials: XX
authors.lastname: Chen
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Liang-Ping
authors.initials: LP
authors.lastname: Xia
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People; D018572:Disease-Free Survival; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel